Stromal Therapeutics
Stromal Therapeutics AG is a Swiss biotech company developing novel therapies targeting stromal cells, with a primary focus on cardiovascular diseases. Our lead antibody, STx_001, has been successfully humanized and has demonstrated in vivo efficacy in models of acute myocarditis.Preclinical safety data support IND preparation, with a First-in-Human trial planned for 2026. The company is currently seeking Series A financing to advance clinical development.
Date, time and room information
May 5, 15:30 - 15:45, room Singapore
Category
Emerging biotech company
Title of the presentation
Tissue stroma manipulation to create novel therapies
Speaker information
| Name | Position | Institution |
|---|---|---|
| Burkhard Ludewig | Chair of the board |
